Commercial Eugenics -- From CRISPR to eGenesis, Academic Eugenics Transitioning to Market

Eugenisme Commercial -- De CRISPR a eGenesis, transition de l'eugenisme academique vers le marche

Plausible

0.5

Credibility score

Eugenics & Science BiotechnologieInvestissementEugenisme Grey zone

Summary

Epstein’s interest in biotechnology was not purely philanthropic but included attempts at commercial investment. 10 documents within the corpus trace the attempt to invest $1.5M in eGenesis (George Church’s startup for porcine xenotransplantation) between 2014 and 2016. Boris Nikolic (former science advisor to Bill Gates) served as an intermediary. Meetings took place at the Harvard PED premises (funded by Epstein). This theory explores the transition from academic interest (PED/Nowak) to commercial applications (CRISPR, eGenesis, potentially Genomic Prediction).

Detailed description

eGenesis Timeline

Oct 2014 (EFTA00360437) : Luhan Yang (Harvard Genetics, co-founder of eGenesis) proposes to Epstein: $1.5M for 9.09% eGenesis (pre-money $15M) or a convertible note at a 15% discount/8% interest. Mission: 'Deliver human transplantable organ by engineering animals.' James Clement in CC.
Oct 2015 (EFTA00639365) : Subject 'georgarage pigs'. Epstein writes to Church: 'george garage pigs?' Church responds by connecting with Geoff MacKay (CEO eGenesis). Georgarage LLC = LLC of Church.
Dec 2015 (EFTA00666292) : Nikolic to Epstein: 'george is asking for his money at a $27m valuation. what would you like me to do?' Nikolic: '$27MM is totally crazy. I would go to $7MM...they do not realize how inexperienced they are.' Cites Editas, Intellia, Crispr TX as comparables.
Feb 2016 (EFTA00329546-p2) : Lesley Groff organizes meeting: 'Jeffrey Epstein will be up at Harvard this Friday Feb. 5th and hopes he can meet with [Luhan and Geoff] at 3pm at Martin Nowak's Institute at 1 Brattle Square, Suite 6.' The PED (financed by Epstein) serves as a meeting room for biotech deals.
Feb 2016 (EFTA00654011) : Epstein writes to Church 'skype Luhan?' Yang invites Epstein to discuss 'eGenesis investment opportunities.'

Pattern Y: Biotech Investment as Normalization

eGenesis was a REEL investment but also served as a tool of normalization:

Church = financially dependent (PED lab + startup eGenesis funded by the same source)
Meetings in the PED offices normalize Epstein's presence on the Harvard campus
Nikolic (ex-Gates) = institutional guarantor
The legitimate investment serves as a facade for continued attendance

'Kosher Pig' Connection

The concept of the 'kosher pig' (genetically modified pig to become kosher) is DISTINCT from xenotransplantation. The corpus contains NO reference to the concept of a kosher pig. The eGenesis investment was motivated by medical xenotransplantation (organ transplantation), NOT by religious considerations.

Distinction with THEORY-0005

THEORY-0005 covers the global scientific network (MIT/Harvard/transhumanism). THEORY-0046 focuses specifically on the COMMERCIAL and INVESTMENT dimension of the Epstein-biotech relationship. The PED financed basic research; eGenesis represents the attempt to monetize that research.

Key claims

Oct 2014** (EFTA00360437) : Luhan Yang (Harvard Genetics, co-fondatrice eGenesis) propose a Epstein : $1.5M pour 9.09% eGenesis (pre-money $15M) ou note convertible 15% discount/8% interet.

Mission : 'Deliver human transplantable organ by engineering animals.' James Clement en CC.

Oct 2015** (EFTA00639365) : Sujet 'georgarage pigs'.

Epstein ecrit a Church : 'geroge garage pigs?' Church repond en connectant avec Geoff MacKay (CEO eGenesis).

Dec 2015** (EFTA00666292) : Nikolic a Epstein : 'george is asking for his money at a 27m valuation.

Factchecks (1)

FC-0078 [PARTIELLEMENT VRAI — INVESTISSEMENTS DOCUMENTÉS, 'EUGÉNISME COMMERCIAL' INTERPRÉTATIF] 62% Le Factchecker 2026-02-27

Claim checked

L'intérêt d'Epstein pour la biotechnologie incluait des tentatives d'investissement commercial (CRISPR, eGenesis) marquant une transition de l'eugénisme idéologique vers l'eugénisme commercial.

Summary

CONFIRMÉ DANS LE CORPUS: (1) Des documents retracent des tentatives d'investissement d'Epstein dans des entreprises biotech. (2) George Church (Harvard) avait des liens avec Epstein — CONFIRMÉ (il a admis avoir reçu des fonds). (3) eGenesis (xénotransplantation) a été cofondé par des chercheurs que fréquentait Epstein. (4) L'intérêt pour CRISPR est documenté dans les emails. NUANCÉ: (1) 'Eugénisme commercial' est une GRILLE ANALYTIQUE — investir dans la biotech n'est pas de l'eugénisme per se. (2) La 'transition idéologique vers commercial' est une interprétation. (3) Beaucoup d'investisseurs investissent dans la biotech sans intention eugéniste. Score ajusté: 0.55 → 0.50.